🚀 VC round data is live in beta, check it out!
Q32 Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Q32 Bio and similar public comparables like Herantis Pharma, Oncocross, Entera Bio, LTR Pharma and more.
Q32 Bio Overview
About Q32 Bio
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
Founded
2015
HQ
Employees
42
Website
Sectors
Financials (LTM)
EV
$32M
Q32 Bio Financials
Q32 Bio reported last 12-month revenue of $42M and EBITDA of $6M.
In the same LTM period, Q32 Bio generated $42M in gross profit, $6M in EBITDA, and $15M in net income.
Revenue (LTM)
Q32 Bio P&L
In the most recent fiscal year, Q32 Bio reported revenue of $54M and EBITDA of $31M.
Q32 Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $42M | XXX | $54M | XXX | XXX | XXX |
| Gross Profit | $42M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | $6M | XXX | $31M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 58% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $15M | XXX | $30M | XXX | XXX | XXX |
| Net Margin | 36% | XXX | 56% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Q32 Bio Stock Performance
Q32 Bio has current market cap of $64M, and enterprise value of $32M.
Market Cap Evolution
Q32 Bio's stock price is $4.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32M | $64M | 0.0% | XXX | XXX | XXX | $2.32 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialQ32 Bio Valuation Multiples
Q32 Bio trades at 0.8x EV/Revenue multiple, and 5.6x EV/EBITDA.
EV / Revenue (LTM)
Q32 Bio Financial Valuation Multiples
As of March 21, 2026, Q32 Bio has market cap of $64M and EV of $32M.
Equity research analysts estimate Q32 Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Q32 Bio has a P/E ratio of 4.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $64M | XXX | $64M | XXX | XXX | XXX |
| EV (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 5.6x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBIT | 7.3x | XXX | 1.9x | XXX | XXX | XXX |
| EV/Gross Profit | 0.8x | XXX | — | XXX | XXX | XXX |
| P/E | 4.2x | XXX | 2.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Q32 Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Q32 Bio Margins & Growth Rates
Q32 Bio's revenue in the last 12 month declined by (100%).
Q32 Bio's revenue per employee in the last FY averaged $1.0M.
Q32 Bio's rule of 40 is (87%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Q32 Bio's rule of X is (237%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Q32 Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 58% | XXX | XXX | XXX |
| EBITDA Growth | (743%) | XXX | (212%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (87%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (237%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 43% | XXX | 33% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 47% | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Q32 Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Herantis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncocross | XXX | XXX | XXX | XXX | XXX | XXX |
| Entera Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Grace Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Q32 Bio M&A Activity
Q32 Bio acquired XXX companies to date.
Last acquisition by Q32 Bio was on XXXXXXXX, XXXXX. Q32 Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Q32 Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialQ32 Bio Investment Activity
Q32 Bio invested in XXX companies to date.
Q32 Bio made its latest investment on XXXXXXXX, XXXXX. Q32 Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Q32 Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Q32 Bio
| When was Q32 Bio founded? | Q32 Bio was founded in 2015. |
| Where is Q32 Bio headquartered? | Q32 Bio is headquartered in United States. |
| How many employees does Q32 Bio have? | As of today, Q32 Bio has over 42 employees. |
| Who is the CEO of Q32 Bio? | Q32 Bio's CEO is Jodie P. Morrison. |
| Is Q32 Bio publicly listed? | Yes, Q32 Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Q32 Bio? | Q32 Bio trades under QTTB ticker. |
| When did Q32 Bio go public? | Q32 Bio went public in 2024. |
| Who are competitors of Q32 Bio? | Q32 Bio main competitors are Herantis Pharma, Oncocross, Entera Bio, LTR Pharma. |
| What is the current market cap of Q32 Bio? | Q32 Bio's current market cap is $64M. |
| What is the current revenue of Q32 Bio? | Q32 Bio's last 12 months revenue is $42M. |
| What is the current revenue growth of Q32 Bio? | Q32 Bio revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Q32 Bio? | Current revenue multiple of Q32 Bio is 0.8x. |
| Is Q32 Bio profitable? | Yes, Q32 Bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Q32 Bio? | Q32 Bio's last 12 months EBITDA is $6M. |
| What is Q32 Bio's EBITDA margin? | Q32 Bio's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Q32 Bio? | Current EBITDA multiple of Q32 Bio is 5.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.